For example, in addition to specific inhibitors of KRAS G12C (which are predominant in NSCLC) inhibitors targeting other frequent substitution of KRAS are getting closer to entering clinical trials (for example MRTX1133 for KRAS G12D, a KRAS mutation frequent in gastrointestinal cancer). This evidence concerns the gene KRAS and non-small cell lung carcinoma.